Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy

Jayson Rapoport, Marcus Mostoslavski, Aharon Ben-David, Aharon Knecht, Alexander Blau, Jacob Arad, Moshe Zlotnik, Cidio Chaimovitz

    Research output: Contribution to journalArticlepeer-review

    9 Scopus citations

    Abstract

    We have used high-dose oral pulse therapy with 1α-hydroxycholecalciferol (1α –OH-D3) to treat 40 hemodialysis patients suffering from secondary hyperparathyroidism. Forty patients with intact parathyroid hormone (PTH) levels of > 150 pg/ml were treated with 4 μg oral 1α-OH-D3 twice weekly for 1 year. The mean PTH level was 515 ± 50 pg/ml prior to treatment, which fell to 191 ± 42 pg/ml after 6 months of treatment (p < 0.00001), and to 164 ± 39 pg/ml after 12 months of treatment. Patients with very high PTH levels (> 800 pg/ml) suppressed less well than patients with lower levels (150-300 pg/ml). The therapeutic end point of PTH < 100 pg/ml was achieved in 23 patients (58%). The main side effect of the treatment was hypercalcemia, but this was symptomatic in only 3 patients, all above the age of 70 years. In summary, oral high-dose pulse therapy with 1α -OH-D3 was highly effective in suppressing PTH levels in hyperparathyroid hemodialysis patients, and side effects were relatively few.

    Original languageEnglish
    Pages (from-to)150-154
    Number of pages5
    JournalNephron
    Volume72
    Issue number2
    DOIs
    StatePublished - 1 Jan 1996

    Keywords

    • 1α-Hydroxycholecalciferol
    • Hemodialysis
    • Hypercalcemia
    • Hyperparathyroidism
    • Pulse therapy

    Fingerprint

    Dive into the research topics of 'Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy'. Together they form a unique fingerprint.

    Cite this